Healthcare provider profile · identity verified

Alla Chesky, MD

Internal Medicine · FAIRFIELD, CT · NPI 1194707463

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	337	112
Rosuvastatin Calcium	Rosuvastatin Calcium	297	85
Amlodipine Besylate	Amlodipine Besylate	256	79
Lisinopril	Lisinopril	203	59
Levothyroxine Sodium	Levothyroxine Sodium	167	50
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	153	40
Zolpidem Tartrate	Zolpidem Tartrate	140	28
Metoprolol Succinate	Metoprolol Succinate	120	36
Duloxetine Hcl	Duloxetine Hcl	106	35
Escitalopram Oxalate	Escitalopram Oxalate	98	28
Losartan Potassium	Losartan Potassium	89	25
Ozempic	Semaglutide	79	19
Chlorthalidone	Chlorthalidone	74	24
Metformin Hcl	Metformin Hcl	74	25
Trazodone Hcl	Trazodone Hcl	71	23
Jardiance	Empagliflozin	65	16
Carvedilol	Carvedilol	61	17
Diclofenac Sodium	Diclofenac Sodium	61	20
Pantoprazole Sodium	Pantoprazole Sodium	61	21
Fluticasone Propionate	Fluticasone Propionate	60	19
Omeprazole	Omeprazole	60	21
Olmesartan Medoxomil	Olmesartan Medoxomil	59	16
Gabapentin	Gabapentin	57	18
Alprazolam	Alprazolam	54	17
Eliquis	Apixaban	52	18
Albuterol Sulfate Hfa	Albuterol Sulfate	45	24
Simvastatin	Simvastatin	43	11
Synthroid	Levothyroxine Sodium	40	12
Metformin Hcl Er	Metformin Hcl	36	13
Hydrochlorothiazide	Hydrochlorothiazide	35	13
Ibandronate Sodium	Ibandronate Sodium	34	suppressed
Glipizide Er	Glipizide	32	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	30	12
Montelukast Sodium	Montelukast Sodium	30	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	28	suppressed
Bupropion Xl	Bupropion Hcl	27	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	27	11
Famotidine	Famotidine	26	suppressed
Furosemide	Furosemide	26	suppressed
Paroxetine Hcl	Paroxetine Hcl	26	suppressed
Valsartan	Valsartan	26	12
Ventolin Hfa	Albuterol Sulfate	25	suppressed
Symbicort	Budesonide/Formoterol Fumarate	24	suppressed
Allopurinol	Allopurinol	23	suppressed
Colchicine	Colchicine	23	suppressed
Hydralazine Hcl	Hydralazine Hcl	23	suppressed
Donepezil Hcl	Donepezil Hcl	21	suppressed
Nystatin	Nystatin	21	suppressed
Citalopram Hbr	Citalopram Hydrobromide	20	suppressed
Alendronate Sodium	Alendronate Sodium	19	suppressed
Pravastatin Sodium	Pravastatin Sodium	19	suppressed
Clopidogrel	Clopidogrel Bisulfate	18	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Sertraline Hcl	Sertraline Hcl	18	suppressed
Diclofenac Potassium	Diclofenac Potassium	17	suppressed
Azithromycin	Azithromycin	16	13
Xarelto	Rivaroxaban	16	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	15	suppressed
Meloxicam	Meloxicam	15	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	15	15
Atenolol	Atenolol	14	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	14	13
Januvia	Sitagliptin Phosphate	14	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	14	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	14	suppressed
Finasteride	Finasteride	13	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	13	suppressed
Mometasone Furoate	Mometasone Furoate	13	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	13	11
Potassium Chloride	Potassium Chloride	13	suppressed
Pregabalin	Pregabalin	13	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Ramipril	Ramipril	12	suppressed
Rybelsus	Semaglutide	12	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	12	suppressed
Trueplus Pen Needle	Pen Needle, Diabetic	12	suppressed
Diazepam	Diazepam	11	suppressed
Levetiracetam	Levetiracetam	11	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	11	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	11	suppressed
Oxycontin	Oxycodone Hcl	11	suppressed
Tramadol Hcl	Tramadol Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error